The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 9 of the 27 sources its claims cite were checked for support.
Identification of bacteria-derived HLA-bound peptides in melanoma
Open accessAbstract
A variety of species of bacteria are known to colonize human tumours 1-11, proliferate within them and modulate immune function, which ultimately affects the survival of patients with cancer and their responses to treatment 12-14. However, it is not known whether antigens derived from intracellular bacteria are presented by the human leukocyte antigen class I and II (HLA-I and HLA-II, respectively) molecules of tumour cells, or whether such antigens elicit a tumour-infiltrating T cell immune response. Here we used 16S rRNA gene sequencing and HLA peptidomics to identify a peptide repertoire derived from intracellular bacteria that was presented on HLA-I and HLA-II molecules in melanoma tumours. Our analysis of 17 melanoma metastases (derived from 9 patients) revealed 248 and 35 unique HLA-I and HLA-II peptides, respectively, that were derived from 41 species of bacteria. We identified recurrent bacterial peptides in tumours from different patients, as well as in different tumours from the same patient. Our study reveals that peptides derived from intracellular bacteria can be presented by tumour cells and elicit immune reactivity, and thus provides insight into a mechanism by which bacteria influence activation of the immune system and responses to therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 Valid · 0 Not valid · 3 Not checked · 84 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a property that might make these peptides preferable for antigen presentation16 and recognition by T cells17”
§ Identification of bacteria-derived HLA-bound peptides in melanoma > Presentation of bacterial peptides
What the sources say
- Partly supportedcites [16] Vigneron, N., Abi Habib, J. & Van den Eynde, B. J. Learning from the proteasome how to fine-tune cancer immunotherapy. Trends Cancer 3, 726–741 (2017). sourceExperimental — accuracy not yet measured
Our copy of Vigneron et al. (2017) states the general principle the claim rests on — in section 3.1.3.1 (Standard and immunproteasome) it says HLA class I binding 'generally calls for peptides with hydrophobic or basic C-termini', so peptides with such ends are 'more likely to bind HLA-molecules with high affinity', with downstream consequences for CTL recognition (section 3, Processing of tumor antigens; Text Box 2). What it does not contain is the bacterial part of the claim: no passage compares bacterial peptides with self/eukaryotic peptides or addresses their hydrophobicity — searches for 'bacterial peptides', 'bacteria', 'microbiota/pathogen-derived antigens' returned only viral-antigen and proteasome-subunit material (sections 2.1.1, 3.1.3.1). The attributing sentence's premise of greater hydrophobicity of bacterial peptides is therefore not from this source; only the hydrophobicity-favours-presentation half is. (LLM, conf=0.68)
- Partly supportedcites [17] Chowell, D. et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc. Natl Acad. Sci. USA 112, E1754–E1762 (2015). sourceExperimental — accuracy not yet measured
Chowell et al. 2015 do support the general mechanism the claim rests on: the Discussion states that 'protein hydrophobicity can enhance both antigen presentation and immunogenicity' and that covering exposed hydrophobic residues by a TCR 'may be a thermodynamically favorable process, facilitating the pMHC–TCR interaction' (same hedged register as the citing 'might'). However, the bacterial specificity is not supported: our copy's immunogenic dataset is dominated by intracellular pathogens 'such as viruses', and the authors only speculate that 'pathogens generally have a greater use of hydrophobic amino acids'; they explicitly report no significant hydrophobicity difference between pathogen-derived and self immunogenic epitopes (Results, SI Appendix Fig. S2G). Additionally, the antigen-presentation half is largely a synthesis of another work the paper credits (Huang, Kuhls & Eisenlohr, ref 29), and the presentation/enhancement claim sits alongside the paper's own finding, which is selective for TCR contact residues rather than anchors. (LLM, conf=0.72)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We demonstrate that bacterial HLA-I and HLA-II peptides can be presented by both antigen-presenting cells (as has previously been shown25–28) and by melanoma cells”
§ Identification of bacteria-derived HLA-bound peptides in melanoma > Discussion
What the sources say
- Supportedcites [25] Bettencourt, P. et al. Identification of antigens presented by MHC for vaccines against tuberculosis. NPJ Vaccines 5, 2 (2020). source
The citation is attached to the prior finding about antigen-presenting cells, not the citing authors’ finding about melanoma cells. The cited paper’s Results section reports both MHC-I and MHC-II BCG peptides in infected macrophages. It does not need to establish the melanoma-cell finding to support this citation. (LLM, conf=0.94)
- Not checked yetcites [26] Pfeifer, J. D. et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359–362 (1993). source
- Not checked yetcites [27] Kovacsovics-Bankowski, M. & Rock, K. L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267, 243–246 (1995). source
- Partly supportedcites [28] Lewinsohn, D. M. et al. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J. Exp. Med. 187, 1633–1640 (1998). sourceExperimental — accuracy not yet measured
The Results and Discussion report presentation of Mycobacterium tuberculosis antigen by infected dendritic cells and macrophages, supporting the antigen-presenting-cell portion of the cited claim. They do not establish presentation of bacterial peptides by both HLA class I and II; the Discussion says the pathway differs from conventional class I and II pathways and that the data do not suggest a direct role for HLA class II. The sentence presents melanoma-cell findings as the citing authors’ own work, not as a finding of this source. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that bacterial proteomes contained a significantly higher fraction of hydrophobic amino acids compared to the human proteome”
§ Identification of bacteria-derived HLA-bound peptides in melanoma > Presentation of bacterial peptides
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the HLA-C*03:04, HLA-C*03:03 and HLA-A*02:01 alleles bind to more hydrophobic peptides”
§ Identification of bacteria-derived HLA-bound peptides in melanoma > Presentation of bacterial peptides
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“bacteria-derived peptides were significantly more hydrophobic (unpaired two-sample Wilcoxon test, P = 3.71 × 10−46)”
§ Identification of bacteria-derived HLA-bound peptides in melanoma > Presentation of bacterial peptides
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
55 more claims
Create a free account to see all 90 claims and to verify the 18 references still open.
- It may state two separate claims as one. 29
- The quote only partly states this claim. 1
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intracellular bacteria contained in metastatic melanoma cells enable the binding of bacterial peptides to major histocompatibility complex class I and II molecules, thereby facilitating tumor recognition and killing by tumor-infiltrating lymphocytes.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Theoretically, more than one bacterial cell can infect a single cancer cell,38,103 but the total number of unique species per tumor, bacterial or fungal, drops (<50) when decontamination strategies are applied.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A growing body of evidence has demonstrated the presence of intratumoral microbes, with studies using either metagenomics or culturomics suggesting the presence of intracellular,14,38,102,103 cancer type-specific,14,104–106 spatially heterogeneous,14,103,107 metabolically active,14,38,49,108,109 pro-metastatic,102,103,110,111 and immunoreactive38,60,112–115 communities of tumor-resident bacteria,”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“this is one possible mechanism by which intratumoral bacteria could directly impact anti-tumor immunity”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Kalaora et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Peptides derived from intracellular bacteria can be presented by tumor cells in the context of human HLA-I and -II and recognized by tumor-infiltrating T-cells”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Kalaora et al., 2021
Citations
Cites
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationTumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.027 · Cited by 981
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer
Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., Futran, N., Houlton, J., Sather, C., Sicinska, E., et al. (2022) · Nature · doi:10.1038/s41586-022-05435-0 · Cited by 887
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Self-citationPan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions
Narunsky-Haziza, L., Sepich-Poore, G. D., Livyatan, I., Asraf, O., Martino, C., Nejman, D., Gavert, N., Stajich, J. E., Amit, G., González, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.005 · Cited by 538
“Recent studies found metabolically active, immunoreactive, intracellular, and cancer type-specific communities of bacteria and viruses in tumor tissues (Geller et al., 2017; Kalaora et al., 2021; Le Noci et al., 2018; Mima et al., 2015; Nejman et al., 2020; Parhi et al., 2020; Poore et al., 2020; Pushalkar et al., 201…”
BackgroundSelf-citation
Metadata
- Authors
- Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., Bussi, Y., Rotkopf, R., Levy, R., Benedek, G., Trabish, S., Dadosh, T., Levin-Zaidman, S., Geller, L. T., Wang, K., Greenberg, P., Yagel, G., Peri, A., Fuks, G., Bhardwaj, N., Reuben, A., Hermida, L., Johnson, S. B., Galloway-Peña, J. R., Shropshire, W. C., Bernatchez, C., Haymaker, C., Arora, R., Roitman, L., Eilam, R., Weinberger, A., Lotan-Pompan, M., Lotem, M., Admon, A., Levin, Y., Lawley, T. D., Adams, D. J., Levesque, M. P., Besser, M. J., Schachter, J., Golani, O., Segal, E., Geva-Zatorsky, N., Ruppin, E., Kvistborg, P., Peterson, S. N., Wargo, J. A., Straussman, R., & Samuels, Y.
- Affiliations
- Weizmann Institute of Science (IL)
- Technion – Israel Institute of Technology (IL)
- The Netherlands Cancer Institute (NL)
- National Institutes of Health (US)
- Open University of Israel (IL)
- Hadassah Medical Center (IL)
- The University of Texas MD Anderson Cancer Center (US)
- Texas A&M University (US)
- Wellcome Sanger Institute (GB)
- University of Zurich (CH)
- Tel Aviv University (IL)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Samuels, Yardena
- ORCID
- Kalaora, Shelly
- Nagler, Adi
- Nejman, Deborah
- Barnea, Eilon
- Ketelaars, Steven L. C.
- Cheng, Kuoyuan
- Shental, Noam
- Bussi, Yuval
- Rotkopf, Ron
- Levy, Ronen
- Benedek, Gil
- Geller, Leore T.
- Wang, Kun
- Greenberg, Polina
- Yagel, Gal
- Peri, Aviyah
- Fuks, Garold
- Reuben, Alexandre
- Hermida, Leandro
- Johnson, Sarah B.
- Galloway-Peña, Jessica R.
- Shropshire, William C.
- Bernatchez, Chantale
- Haymaker, Cara
- Arora, Reetakshi
- Roitman, Lior
- Weinberger, Adina
- Lotem, Michal
- Admon, Arie
- Levin, Yishai
- Lawley, Trevor D.
- Adams, David J.
- Levesque, Mitchell P.
- Besser, Michal J.
- Schachter, Jacob
- Golani, Ofra
- Segal, Eran
- Geva-Zatorsky, Naama
- Ruppin, Eytan
- Kvistborg, Pia
- Wargo, Jennifer A.
- Straussman, Ravid
- Samuels, Yardena
- Venue
- Nature
- Published
- 2021-03-17
- Volume
- 592
- Issue
- 7852
- Pages
- 138-143
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC9717498
- OpenAlex
- W3137683977
- Cited by
- 457
- References
- 51
- Citations by year
- 2026: 73 · 2025: 93 · 2024: 83 · 2023: 87 · 2022: 83 · 2021: 36
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Wellcome Trust (WT 098051)
- National Institutes of Health
- Medical Research Council (MR/V000292/1)
- National Cancer Institute (P30CA016672)
- National Institute of Allergy and Infectious Diseases (K01AI143881)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- melanoma, intracellular bacteria, bacterial antigens, HLA-bound peptides, tumor-infiltrating T cells, HLA class I, HLA class II, cancer immunotherapy, antitumor immunity
- MeSH terms
- Antigens, Bacterial, Bacteria, HLA Antigens, Humans, Melanoma, Neoplasm Metastasis, Peptides, Phylogeny, RNA, Ribosomal, 16S, Lymphocytes, Tumor-Infiltrating, Antigen Presentation, Coculture Techniques, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of bacteria-derived HLA-bound peptides in melanoma. https://app.cochat.ai/papers/10.1038/s41586-021-03368-8
- The paper
- Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., Bussi, Y., Rotkopf, R., Levy, R., Benedek, G., Trabish, S., Dadosh, T., Levin-Zaidman, S., Geller, L. T., Wang, K., . . . Samuels, Y. (2021). Identification of bacteria-derived HLA-bound peptides in melanoma. Nature. https://doi.org/10.1038/s41586-021-03368-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.